PDF factsheet
      Z

cholesterol lowering intervention in heart failure for all type of patients, clinical trials results

atorvastatin versus control
Wojnicz, 2006
atorvastatin 40 mg/day
versus
conventional treatment for heart failure
patients with inflammatory dilated cardiomyopathy (DC) (positive immunohistochemistry results on endomyocardial biopsy)open
Follow-up duration: 6 months
Yamada, 2007
atorvastatin 10 mg/d
versus
standard treatment
outpatients with mild to moderate CHF and radionuclide left ventricular ejection fraction (LVEF) <40%
Follow-up duration: mean 2.58y
atorvastatin versus placebo
Strey, 2005
atorvastatin 40mg
versus
placebo
patients with stable, symptomatic heart failure (New York Heart Association Class II or III) and a left ventricular ejection fraction <40%
Follow-up duration: 6 weeks
Sola, 2006
atorvastatin 20 mg/day
versus
placebo
patients with nonischemic HF and a left ventricular ejection fraction (LVEF) <=35%double blind
Follow-up duration: 1y
cerivastatin versus placebo
Laufs, 2004
cerivastatin 0.4 mg
versus
placebo
patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathydouble blind
Follow-up duration: mean 20 weeks
rosuvastatin versus placebo
CORONA, 2007
NCT00206310
rosuvastatin 10mg/d
versus
placebo
patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failuredouble blind
Follow-up duration: 32.9 months median
Krum, 2007
rosuvastatine 40mg/d
versus
placebo
patients with systolic (LVEF<40%) CHF of ischemic or nonischemic etiologydouble blind
Follow-up duration: 6 months
Australia
GISSI-HF rosuvastatine, 2008
NCT00336336
low-dose rosuvastatin 10 mg daily
versus
placebo
Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapydouble blind
Follow-up duration: 3.9y median (IQR 3-4.4)
Italy
simvastatin versus control
Hong, 2005
simvastatin
versus
no treatment
patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%)open
Follow-up duration: 1 year
simvastatin versus ezetimibe
Landmesser, 2005
simvastatin 10mg/d
versus
ezetimibe 10mg/d
patients with chronic heart failure
simvastatin versus placebo
Node, 2003
simvastatin 10mg/d
versus
placebo
patients with symptomatic, nonischemic, dilated cardiomyopathy

  Options


in first

in second

  Filter